ACRP to Celebrate Clinical Trials Day May 20
The Association of Clinical Research Professionals (ACRP) is officially partnering with the European Clinical Research Infrastructures Network (ECRIN) in honoring the extraordinary contributions of clinical researchers worldwide on International Clinical Trials? Day--May 20. ECRIN launched the day in 2006 for organizations, clinical research professionals, and the public to acknowledge the life changing achievements that result from the work performed by clinical researchers.
ACRP To Celebrate International Clinical Trials' Day
The Association of Clinical Research Professionals (ACRP) is officially partnering with the European Clinical Research Infrastructures Network (ECRIN) in honoring the extraordinary contributions of clinical researchers worldwide on International Clinical Trials’ Day--May 20. ECRIN launched the day in 2006 for organizations, clinical research professionals, and the public to acknowledge the life changing achievements that result from the work performed by clinical researchers. ACRP will serve as the platform for its extensive network of member and member companies to voice their pride and passion for the essential work they are accomplishing on a daily basis by posting stories of participants via CISCRP; and posting achievements and more via its LinkedIn, Twitter, Facebook, Instagram and at its targeted web site.
Link here for the full press release.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Final ENLIVEN Trial Results Confirm Long-Term Benefit of Turalio in Tenosynovial Giant Cell Tumor
July 9th 2025In final data from the Phase III ENLIVEN study, Turalio (pexidartinib) demonstrated durable tumor responses and a consistent safety profile in patients with symptomatic TGCT not amenable to surgery.
